Additional file 1 of SGLT-2 inhibitors and in-stent restenosis-related events after acute myocardial infarction: an observational study in patients with type 2 diabetes
Additional file 1: Supplementary Figure 1. Risk of ISR-related MACE according to the use of different SGLT2i. Kaplan-Meier curves showing the risk of MACE in patients treated with either empagliflozin, canagliflozin, or dapagliflozin and compared with no-SGLT2i users, along with the relative values derived from Log Rank tests. No differences were observed between different drugs.